Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $56.63.
Several analysts have issued reports on PTCT shares. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $58.00 price objective on shares of PTC Therapeutics in a research report on Thursday. Credit Suisse Group reaffirmed a “buy” rating and set a $54.00 price objective on shares of PTC Therapeutics in a research report on Thursday, October 31st. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, October 30th. Finally, SunTrust Banks began coverage on PTC Therapeutics in a research report on Tuesday, November 12th. They set a “buy” rating and a $78.00 target price on the stock.
In other news, CEO Stuart Walter Peltz sold 22,463 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $49.43, for a total value of $1,110,346.09. Corporate insiders own 7.00% of the company’s stock.
Shares of PTC Therapeutics stock opened at $49.20 on Friday. The company’s fifty day simple moving average is $42.36 and its 200-day simple moving average is $42.01. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -26.74 and a beta of 1.90. The company has a current ratio of 4.40, a quick ratio of 4.30 and a debt-to-equity ratio of 0.44. PTC Therapeutics has a 1 year low of $27.53 and a 1 year high of $50.96.
PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.15). PTC Therapeutics had a negative return on equity of 31.92% and a negative net margin of 74.86%. The company had revenue of $71.40 million for the quarter, compared to the consensus estimate of $72.03 million. During the same period last year, the firm posted ($1.06) EPS. The company’s revenue was up 33.2% compared to the same quarter last year. As a group, research analysts forecast that PTC Therapeutics will post -3.1 earnings per share for the current fiscal year.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.